All In Biotech

Drug Trial Radar · NCT07447297

Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Jan 2, 2024

Primary completion

Dec 15, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Korea University Guro Hospital; Korea University Anam Hospital; Keimyung University Dongsan Medical Center; Severance Hospital; Wonju Severance Christian Hospital; Asan Medical Center; Inje University Ilsan Paik Hospital; The Catholic University of Korea
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study to find out the efficacy of early rhythm therapy in patients with subclinical atrial fibrillation detected by Cardiac Electronic Implantable Devices. Early rhythm therapy includes antiarrhythmic drug, cardioversion, and catheter ablation. The general control group receives general management without the above atrial fibrillation rhythm control treatment. Researchers will compare early rhythm control groups to general control groups to see if early rhythm therapy works to reduce the atrial fibrillation burden by 50% or more, or decrease the incidence of clinical AF documentation. Participants will: * Randomly allocated to two groups at a 1:1 ratio. * Receive the treatment according to their assigned group. * Visit the clinic once every three months for checkups and tests.

Conditions

  • Atrial Fibrillation (AF)
  • Diseases of the Circulatory System
  • Atrial Flutter

Interventions

  • early rhythm control groupDrug

    flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone and so on

  • cardioversion, catheter ablationProcedure

    only when clinical atrial fibrillation (if atrial fibrillation continued for more than 30 seconds on a 12-lead electrocardiogram or holter monitoring) is confirmed

  • general controlOther

    General management without atrial fibrillation rhythm control treatment.(Observation without additional medication, or heart rate control treatment if necessary) Heart rate control drugs such as beta-blockers, calcium channel blockers (Non-dihydropyridine CCB), and digoxin are used for heart rate control according to the doctor's prescription.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Less than 50% reduction in atrial fibrillation(AF) burden or clinical AF documentation Incidence Rate (AF recurrence rate)Time frame: From enrollment to 1 year
  2. side effects related to medication or other treatmentsTime frame: From enrollment to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.